Cargando…
KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study
BACKGROUND: Inhibitors of the epidermal growth factor (EGFR) signaling pathway have a major role in the treatment of KRAS wild-type colorectal cancer patients. The EGFR pathway has been shown to be activated in gastric cancer (GC). However, published data on KRAS and BRAF mutation status is limited...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629423/ https://www.ncbi.nlm.nih.gov/pubmed/23511561 http://dx.doi.org/10.1038/bjc.2013.109 |
_version_ | 1782266579344424960 |
---|---|
author | van Grieken, N C T Aoyma, T Chambers, P A Bottomley, D Ward, L C Inam, I Buffart, T E Das, K Lim, T Pang, B Zhang, S L Tan, I B Carvalho, B Heideman, D A M Miyagi, Y Kameda, Y Arai, T Meijer, G A Tsuburaya, A Tan, P Yoshikawa, T Grabsch, H I |
author_facet | van Grieken, N C T Aoyma, T Chambers, P A Bottomley, D Ward, L C Inam, I Buffart, T E Das, K Lim, T Pang, B Zhang, S L Tan, I B Carvalho, B Heideman, D A M Miyagi, Y Kameda, Y Arai, T Meijer, G A Tsuburaya, A Tan, P Yoshikawa, T Grabsch, H I |
author_sort | van Grieken, N C T |
collection | PubMed |
description | BACKGROUND: Inhibitors of the epidermal growth factor (EGFR) signaling pathway have a major role in the treatment of KRAS wild-type colorectal cancer patients. The EGFR pathway has been shown to be activated in gastric cancer (GC). However, published data on KRAS and BRAF mutation status is limited in GC and has not been compared between GC from different geographic regions. METHODS: The prevalence of KRAS and BRAF mutations was established in 712 GC: 278 GC from the United Kingdom, 230 GC from Japan and 204 GC from Singapore. The relationship between KRAS/BRAF mutation status, DNA mismatch repair (MMR) status, clinicopathological variables and overall survival was analysed. RESULTS: Overall, 30 (4.2%) GC carried a KRAS mutation. In total, 5.8% of the UK GC, 4% of Japan GC and 1.5% of Singapore GC were KRAS mutant. KRAS mutant GC had fewer lymph node metastases in the UK cohort (P=0.005) and were more frequent in elderly patients in the Japan cohort (P=0.034). KRAS mutations were more frequent in MMR-deficient GC in the UK and the Japanese cohort (P<0.05). A BRAF mutation was only detected in a single Japanese GC. CONCLUSIONS: This large multicentre study demonstrated that KRAS mutations and DNA MMR deficiency have a role in a small subgroup of GC irrespective of country of origin, suggesting that this subgroup of GC may have developed along a common pathway. Further studies need to establish whether concomitant mutations or amplifications of other EGFR signalling pathway genes may contribute to the activation of this pathway in GC. |
format | Online Article Text |
id | pubmed-3629423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-36294232014-04-16 KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study van Grieken, N C T Aoyma, T Chambers, P A Bottomley, D Ward, L C Inam, I Buffart, T E Das, K Lim, T Pang, B Zhang, S L Tan, I B Carvalho, B Heideman, D A M Miyagi, Y Kameda, Y Arai, T Meijer, G A Tsuburaya, A Tan, P Yoshikawa, T Grabsch, H I Br J Cancer Molecular Diagnostics BACKGROUND: Inhibitors of the epidermal growth factor (EGFR) signaling pathway have a major role in the treatment of KRAS wild-type colorectal cancer patients. The EGFR pathway has been shown to be activated in gastric cancer (GC). However, published data on KRAS and BRAF mutation status is limited in GC and has not been compared between GC from different geographic regions. METHODS: The prevalence of KRAS and BRAF mutations was established in 712 GC: 278 GC from the United Kingdom, 230 GC from Japan and 204 GC from Singapore. The relationship between KRAS/BRAF mutation status, DNA mismatch repair (MMR) status, clinicopathological variables and overall survival was analysed. RESULTS: Overall, 30 (4.2%) GC carried a KRAS mutation. In total, 5.8% of the UK GC, 4% of Japan GC and 1.5% of Singapore GC were KRAS mutant. KRAS mutant GC had fewer lymph node metastases in the UK cohort (P=0.005) and were more frequent in elderly patients in the Japan cohort (P=0.034). KRAS mutations were more frequent in MMR-deficient GC in the UK and the Japanese cohort (P<0.05). A BRAF mutation was only detected in a single Japanese GC. CONCLUSIONS: This large multicentre study demonstrated that KRAS mutations and DNA MMR deficiency have a role in a small subgroup of GC irrespective of country of origin, suggesting that this subgroup of GC may have developed along a common pathway. Further studies need to establish whether concomitant mutations or amplifications of other EGFR signalling pathway genes may contribute to the activation of this pathway in GC. Nature Publishing Group 2013-04-16 2013-03-19 /pmc/articles/PMC3629423/ /pubmed/23511561 http://dx.doi.org/10.1038/bjc.2013.109 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Molecular Diagnostics van Grieken, N C T Aoyma, T Chambers, P A Bottomley, D Ward, L C Inam, I Buffart, T E Das, K Lim, T Pang, B Zhang, S L Tan, I B Carvalho, B Heideman, D A M Miyagi, Y Kameda, Y Arai, T Meijer, G A Tsuburaya, A Tan, P Yoshikawa, T Grabsch, H I KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study |
title | KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study |
title_full | KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study |
title_fullStr | KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study |
title_full_unstemmed | KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study |
title_short | KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study |
title_sort | kras and braf mutations are rare and related to dna mismatch repair deficiency in gastric cancer from the east and the west: results from a large international multicentre study |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629423/ https://www.ncbi.nlm.nih.gov/pubmed/23511561 http://dx.doi.org/10.1038/bjc.2013.109 |
work_keys_str_mv | AT vangriekennct krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT aoymat krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT chamberspa krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT bottomleyd krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT wardlc krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT inami krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT buffartte krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT dask krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT limt krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT pangb krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT zhangsl krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT tanib krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT carvalhob krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT heidemandam krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT miyagiy krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT kameday krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT arait krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT meijerga krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT tsuburayaa krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT tanp krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT yoshikawat krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy AT grabschhi krasandbrafmutationsarerareandrelatedtodnamismatchrepairdeficiencyingastriccancerfromtheeastandthewestresultsfromalargeinternationalmulticentrestudy |